Sutro Biopharma (STRO) Liabilities and Shareholders Equity (2017 - 2026)

Sutro Biopharma has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $173.8 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 55.11% year-over-year to $173.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $967.3 million (down 44.14% YoY) and the FY2025 annual result came in at $173.8 million, down 55.11% from the prior year.
• Liabilities and Shareholders Equity slipped to $173.8 million in Q4 2025 per STRO's latest filing, from $209.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $489.0 million in Q2 2024 and troughed at $173.8 million in Q4 2025.
• A 5-year average of $367.6 million and a median of $378.5 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2021 and 2025: Liabilities and Shareholders Equity surged 133.0% in 2021, then slumped 55.11% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $341.4 million in 2021, then climbed by 19.2% to $406.9 million in 2022, then climbed by 15.68% to $470.7 million in 2023, then dropped by 17.74% to $387.2 million in 2024, then plunged by 55.11% to $173.8 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $173.8 million, $209.7 million, and $262.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.